Expanding Workforce Array BioPharma has recently increased its headcount by nearly 100 employees, supported by a 22-acre expansion in Boulder, Colorado. This growth indicates a potential demand for pharmaceuticals, research tools, and operational services to support their scaling efforts.

Strategic Collaborations The company's active partnerships with industry leaders like AstraZeneca, Roche, Genentech, Loxo Oncology, and Cascadian Therapeutics highlight opportunities to collaborate on drug development, licensing, and joint research initiatives that can enhance sales channels and co-marketing.

Focus on Oncology Array specializes in targeted small molecule drugs for cancer treatment, with multiple drugs in development and registration studies. There is a significant opportunity to provide specialized lab equipment, clinical trial services, and personalized medicine solutions tailored for oncology research.

Recent Mergers and Growth Following its acquisition by Pfizer for over $11 billion, Array BioPharma is positioned for accelerated growth. This presents a chance to offer integration technologies, compliance solutions, and enterprise services that align with large pharmaceutical operations.

Market Position and Revenue With a revenue range of $100M to $250M and comparable employee counts to industry giants, Array is a key player in the biopharmaceutical space. Companies providing competitive analysis, market intelligence, and strategic consulting could find valuable sales opportunities here.